SCHEDULE 13D/A: Arif Nasir Ali Reduces Stake in Entero Therapeutics Below 5% Threshold

Sentiment:

Beneficial Ownership Amendment 11 June 2025 1:30 AM

📋All filings for Entero Therapeutics, INC

Arif Nasir Ali and affiliated entities have filed an amended Schedule 13D, indicating a reduction in their beneficial ownership of Entero Therapeutics, Inc. common stock to below the 5% reporting threshold following a recent share sale.

Worse than expectedThe document indicates that a significant beneficial owner, Arif Nasir Ali and his affiliated entities, reduced their stake in Entero Therapeutics, Inc. to below the 5% threshold.This reduction was due to a sale of 20,000 shares by ANARP LLC, which can be interpreted as a negative signal regarding the holder's confidence or investment strategy.

Summary

Arif Nasir Ali, along with Arif Ali IRA Roth, ANARP LLC, and ANANRA LLC TRUST (collectively, the "Reporting Persons"), beneficially owned an aggregate of 230,900 shares of Entero Therapeutics, Inc. common stock as of June 6, 2025.
This aggregate ownership represents approximately 4.85% of the outstanding common stock of Entero Therapeutics, Inc.
The percentage is based on 4,765,729 shares of common stock outstanding, as reported in the company's 10Q filing for the quarter ending March 31, 2025, filed on May 15, 2025.
The Reporting Persons ceased to be beneficial owners of 5% or more of the common stock on June 6, 2025.
ANARP LLC sold 20,000 shares of common stock on June 6, 2025, at a price of $0.50 per share through the open market.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative as a significant beneficial owner has reduced their stake below the 5% threshold through a share sale, which can be perceived as a lack of conviction or a strategic divestment.

Negatives

A significant beneficial owner, Arif Nasir Ali and his affiliated entities, reduced their stake in Entero Therapeutics, Inc. to below the 5% threshold, which can be perceived as a negative signal by investors.
The sale of 20,000 shares by ANARP LLC at $0.50 per share contributed to this reduction in ownership.

Future Outlook

No forward-looking statements or guidance were provided in this document.

Industry Context

This filing is a routine disclosure of a change in beneficial ownership and does not provide broader industry context or trends.

Stakeholder Impact

Shareholders may view the reduction in a significant holder's stake as a negative indicator, potentially impacting investor confidence and the company's stock price.

Key Dates

Date	Description
2025-05-15	Date Entero Therapeutics, Inc. filed its 10Q report for the quarter ending March 31, 2025, reporting 4,765,729 shares of common stock outstanding.
2025-06-06	Date of event which required the filing of this statement; ANARP LLC sold 20,000 shares of common stock, and the Reporting Persons ceased to be beneficial owners of 5% or more of the common stock.
2025-06-09	Date the original Schedule 13D was filed with the U.S. Securities and Exchange Commission.
2025-06-10	Date of signature for the Amendment No. 1 to Schedule 13D.

Recommendation

hold

Keywords

Entero Therapeutics, Schedule 13D, Beneficial Ownership, Stock Sale, Arif Nasir Ali, Common Stock, SEC Filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.